Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Health Technology Assessment

• Publication date

  2025-11-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.3310/DRDR7171PMID 41220181PMCID PMC12668258
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UK adult ADHD services in crisis

  2023cited by this paper
• Predictors of Health-Related Quality of Life in Neurodivergent Children: A Systematic Review

  2023cited by this paper
• The Impact of Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) on Children’s Health-Related Quality of Life: A Systematic Review and Meta-Analysis

  2023cited by this paper
• The Structure and Diagnostic Accuracy of the QbTest in Pediatric ADHD: A Retrospective Clinical Study

  2023cited by this paper
• Evaluating medical tests: introducing the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.

  2023cited by this paper
• Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran

  2023cited by this paper
• Practitioner Review: Clinical utility of the QbTest for the assessment and diagnosis of attention-deficit/hyperactivity disorder - a systematic review and meta-analysis.

  2023cited by this paper
• Using an objective computer task (QbTest) to aid the identification of attention deficit hyperactivity disorder (ADHD) in the Children and Young People Secure Estate (CYPSE): a feasibility randomised controlled trial

  2022cited by this paper
• Efficacy of Continuous Performance Testing in Adult ADHD in a Clinical Sample Using QbTest+

  2022cited by this paper
• ADHD in Children and Adults: Diagnosis and Prognosis.

  2022cited by this paper
• Correction: Metadta: a Stata command for meta-analysis and meta-regression of diagnostic test accuracy data – a tutorial

  2022cited by this paper
• Virtual reality in the diagnostic and therapy for mental disorders: A systematic review.

  2022cited by this paper
• Temporal trends in annual incidence rates for psychiatric disorders and self-harm among children and adolescents in the UK, 2003–2018

  2021cited by this paper
• Quantifying ADHD Symptoms in Open-Ended Everyday Life Contexts With a New Virtual Reality Task

  2021cited by this paper
• Evidence-based pharmacological treatment options for ADHD in children and adolescents.

  2021cited by this paper
• Metadta: a Stata command for meta-analysis and meta-regression of diagnostic test accuracy data – a tutorial

  2021cited by this paper
• QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies

  2021cited by this paper
• The Quantified Behavioral Test—A Confirmatory Test in the Diagnostic Process of Adult ADHD?

  2020cited by this paper
• Optimising medication management in children and young people with ADHD using a computerised test (QbTest): a feasibility randomised controlled trial

  2020cited by this paper
• Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist

  2020cited by this paper
• A systematic review evaluating the implementation of technologies to assess, monitor and treat neurodevelopmental disorders: A map of the current evidence.

  2020cited by this paper
• What Is the Health and Well-Being Burden for Parents Living With a Child With ADHD in the United Kingdom?

  2020cited by this paper
• Video games for the assessment and treatment of attention-deficit/hyperactivity disorder: a systematic review

  2020cited by this paper
• Objective measurement of attention deficit hyperactivity disorder symptoms outside the clinic using the QbCheck: Reliability and validity

  2020cited by this paper
• Is the QbMini a Valid Instrument for ADHD Assessment?

  2020cited by this paper
• FACT: a randomised controlled trial to assess the feasibility of QbTest in the assessment process of attention deficit hyperactivity disorder (ADHD) for young people in prison—a feasibility trial protocol

  2020cited by this paper
• Diagnosing Attention-Deficit/Hyperactivity Disorder (ADHD) in young adults: A qualitative review of the utility of assessment measures and recommendations for improving the diagnostic process

  2019cited by this paper
• Cost-Effectiveness of Treatments in Children With Attention-Deficit/Hyperactivity Disorder: A Continuous-Time Markov Modeling Approach

  2019cited by this paper
• Attention-Deficit/Hyperactivity Disorder, School Performance, and Effect of Medication.

  2019cited by this paper
• TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility

  2019cited by this paper
• Objective assessment of attention‐deficit/hyperactivity disorder in older adults compared with controls using the QbTest

  2019cited by this paper
• RoB 2: a revised tool for assessing risk of bias in randomised trials

  2019cited by this paper
• Incremental clinical utility of continuous performance tests in childhood ADHD – an evidence‐based assessment approach

  2018cited by this paper
• ADHD and the QbTest: Diagnostic Validity of QbTest

  2018cited by this paper
• Diagnosing ADHD in Adults: An Examination of the Discriminative Validity of Neuropsychological Tests and Diagnostic Assessment Instruments

  2018cited by this paper
• Barriers to medication entitlements after diagnosis of ADHD - Authors' reply.

  2018cited by this paper
• Assessing ADHD symptoms in children and adults: evaluating the role of objective measures

  2018cited by this paper
• The Quantified Behavioral Test Failed to Differentiate ADHD in Adolescents With Neurodevelopmental Problems

  2018cited by this paper
• Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis

  2018cited by this paper
• Quality of life of parents of mentally-ill children: a systematic review and meta-analysis

  2018cited by this paper
• Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan

  2018cited by this paper
• Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement

  2018cited by this paper
• The impact of a computerised test of attention and activity (QbTest) on diagnostic decision‐making in children and young people with suspected attention deficit hyperactivity disorder: single‐blind randomised controlled trial

  2018cited by this paper
• Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder

  2017cited by this paper
• ADHD in children and young people: prevalence, care pathways, and service provision.

  2017cited by this paper
• A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK

  2017cited by this paper
• The impact of attention deficit hyperactivity disorder (ADHD) in adulthood: a qualitative study

  2017cited by this paper
• A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder

  2017cited by this paper
• Study of user experience of an objective test (QbTest) to aid ADHD assessment and medication management: a multi-methods approach

  2017cited by this paper
• The clinical utility of the continuous performance test and objective measures of activity for diagnosing and monitoring ADHD in children: a systematic review

  2016cited by this paper
• Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD

  2016cited by this paper
• ROBIS: A new tool to assess risk of bias in systematic reviews was developed

  2016cited by this paper
• The incremental validity of a computerised assessment added to clinical rating scales to differentiate adult ADHD from autism spectrum disorder.

  2016cited by this paper
• The impact of ADHD on the health and well-being of ADHD children and their siblings

  2016cited by this paper
• Is there a difference between child self-ratings and parent proxy-ratings of the quality of life of children with a diagnosis of attention-deficit hyperactivity disorder (ADHD)? A systematic review of the literature

  2016cited by this paper
• ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

  2016cited by this paper
• A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate

  2016cited by this paper
• A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy

  2016cited by this paper
• Innovations in Practice: an objective measure of attention, impulsivity and activity reduces time to confirm attention deficit/hyperactivity disorder diagnosis in children - a completed audit cycle.

  2016cited by this paper
• Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate

  2015cited by this paper
• Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?

  2015cited by this paper
• Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil

  2015cited by this paper
• The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6 to 12 Years of Age With ADHD in a Double-Blind Placebo-Controlled Trial

  2014cited by this paper
• Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.

  2014cited by this paper
• Association between quality of life and treatment response in children with attention Deficit Hyperactivity Disorder and their parents.

  2014cited by this paper
• Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health.

  2014cited by this paper
• Quantitative and subjective behavioural aspects in the assessment of attention-deficit hyperactivity disorder (ADHD) in adults

  2014cited by this paper
• Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study

  2013cited by this paper
• European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

  2013cited by this paper
• Attention-deficit/hyperactivity disorder: are we helping or harming?

  2013cited by this paper
• Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents

  2012cited by this paper
• PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity

  2012cited by this paper
• Objective Measures of Behavior Manifestations in Adult ADHD and Differentiation from Participants with Bipolar II Disorder, Borderline Personality Disorder, Participants with Disconfirmed ADHD as Well as Normative Participants

  2012cited by this paper
• Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

  2012cited by this paper
• German validation of the Conners Adult ADHD Rating Scales (CAARS) II: Reliability, validity, diagnostic sensitivity and specificity

  2012cited by this paper
• Measuring adult Attention Deficit Hyperactivity Disorder using the Quantified Behavior Test Plus

  2012cited by this paper
• Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology

  2012cited by this paper
• Pragmatism as the philosophical foundation for the Joanna Briggs meta-aggregative approach to qualitative evidence synthesis.

  2011cited by this paper
• QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

  2011cited by this paper
• Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis

  2011cited by this paper
• Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

  2011cited by this paper
• Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder

  2009cited by this paper
• Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia

  2009cited by this paper
• The quality of life of children with attention deficit/hyperactivity disorder: a systematic review

  2009cited by this paper
• A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder.

  2009cited by this paper
• Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

  2009cited by this paper
• Long-Acting Methylphenidate-OROS in Youths with Attention-Deficit Hyperactivity Disorder Suboptimally Controlled with Immediate-Release Methylphenidate

  2008cited by this paper
• Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes.

  2008cited by this paper
• Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder

  2008cited by this paper
• A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

  2008cited by this paper
• Validity and clinical feasibility of the ADHD rating scale (ADHD‐RS) A Danish Nationwide Multicenter Study

  2008cited by this paper
• Parent and Teacher SNAP-IV Ratings of Attention Deficit Hyperactivity Disorder Symptoms

  2008cited by this paper
• Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

  2008cited by this paper
• Atomoxetine versus Methylphenidate in Paediatric Outpatients with Attention Deficit Hyperactivity Disorder: A Randomized, Double-Blind Comparison Trial

  2007cited by this paper
• ADHD in children, adolescents, and adults.

  2007cited by this paper
• A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

  2006cited by this paper
• Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach.

  2006cited by this paper
• The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population

  2005cited by this paper
• Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom

  2005cited by this paper
• Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.

  2005cited by this paper

• QbTest for ADHD assessment and medication management: a mixed-methods systematic review of impact on clinical outcomes and patient, carer and clinician experiences

  2025cites this paper